Literature DB >> 2857751

Mannose-resistant hemagglutination and P receptor recognition of uropathogenic Escherichia coli isolated from adult patients.

R M Gander, V L Thomas, M Forland.   

Abstract

Adhesions of 211 strains of uropathogenic Escherichia coli and 19 strains of normal fecal E. coli were characterized by patterns of agglutination with human erythrocytes, Saccharomyces cerevisiae, and horse erythrocytes coated with the P blood-group receptor (P). Mannose-resistant (MR) hemagglutination was significantly associated with P agglutination (P less than .001). E. coli expressing MR and/or P (MR/P) agglutinins concurrently with mannose-sensitive (MS) agglutinins predominated in all clinical categories. The highest percentage of E. coli demonstrating MR/P agglutinins, in the absence of MS agglutinins, was recovered from patients with acute pyelonephritis (35%) compared with percentages of patients with chronic pyelonephritis (13%), asymptomatic bacteriuria (16%), cystitis (11%), and normal fecal control E. coli (11%). Sixty-nine percent of E. coli isolates causing acute pyelonephritis agglutinated P-coated horse erythrocytes compared with only 11% of the fecal isolates. Strains expressing MR/P agglutinins (in the absence of MS agglutinins) isolated from patients with acute pyelonephritis, chronic pyelonephritis, and asymptomatic bacteriuria were significantly associated with the presence of antibody-coated bacteria in patients' urine sediments (P less than .010), an observation indicative of an immune response associated with bacterial invasion of host tissues.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2857751     DOI: 10.1093/infdis/151.3.508

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

1.  Distribution of type 1 and P pili on uropathogenic Escherichia coli O6.

Authors:  R M Gander; V L Thomas
Journal:  Infect Immun       Date:  1987-02       Impact factor: 3.441

2.  Bacterial characteristics in relation to clinical source of Escherichia coli isolates from women with acute cystitis or pyelonephritis and uninfected women.

Authors:  James R Johnson; Krista Owens; Abby Gajewski; Michael A Kuskowski
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

3.  Virulence of Escherichia coli in relation to host factors in women with symptomatic urinary tract infection.

Authors:  T Sandberg; B Kaijser; G Lidin-Janson; K Lincoln; F Orskov; I Orskov; E Stokland; C Svanborg-Edén
Journal:  J Clin Microbiol       Date:  1988-08       Impact factor: 5.948

Review 4.  Virulence factors in Escherichia coli urinary tract infection.

Authors:  J R Johnson
Journal:  Clin Microbiol Rev       Date:  1991-01       Impact factor: 26.132

5.  E. coli virulence factors in children with neurogenic bladder associated with bacteriuria.

Authors:  Eliana B M Guidoni; Vanessa A Dalpra; Patrícia Maria Figueiredo; Domingos da Silva Leite; Lycia Mara J Mímica; Tomomasa Yano; Jesus E Blanco; Julio Toporovski
Journal:  Pediatr Nephrol       Date:  2005-12-31       Impact factor: 3.714

6.  Detection of piluslike structures on clinical and environmental isolates of Vibrio vulnificus.

Authors:  R M Gander; M T LaRocco
Journal:  J Clin Microbiol       Date:  1989-05       Impact factor: 5.948

7.  Utilization of anion-exchange chromatography and monoclonal antibodies to characterize multiple pilus types on a uropathogenic Escherichia coli O6 isolate.

Authors:  R M Gander; V L Thomas
Journal:  Infect Immun       Date:  1986-02       Impact factor: 3.441

8.  Stimulation of human polymorphonuclear leukocyte oxidative metabolism by type 1 pili from Escherichia coli.

Authors:  M B Goetz; F J Silverblatt
Journal:  Infect Immun       Date:  1987-03       Impact factor: 3.441

9.  Rapid and specific detection of the pap, afa, and sfa adhesin-encoding operons in uropathogenic Escherichia coli strains by polymerase chain reaction.

Authors:  C Le Bouguenec; M Archambaud; A Labigne
Journal:  J Clin Microbiol       Date:  1992-05       Impact factor: 5.948

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.